IDH1 mutations are found in more than 70% of WHO grade II/ III astrocytomas and oligodendrogliomas as well as in secondary GB [6], therefore linking IDH1 mutation predominantly to lower grade and grade III gliomas, as well as GB having evolved from the aforementioned. Here, IDH1 is linked to central nervous system cancer.